G&A at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s G&A?
- ArriVent BioPharma, Inc. (AVBP) reported G&A of $8.49M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s G&A changed year-over-year?
- ArriVent BioPharma, Inc.'s G&A increased by 54.9% year-over-year, from $5.48M to $8.49M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s G&A?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s G&A has grown at a 57.8% compound annual growth rate (CAGR), from $9.71M to $24.18M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.